Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity

Fig. 1

Schematic of the “double-attack” strategy: bispecific antibody combined with PEGylated liposomal doxorubicin. The bispecific antibody (CD20 mAb-mPEG scFv) can simultaneously target the systemic liquid tumor cells, retain the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (first attack). After PLD injection, the CD20 Ab-mPEG scFv on the membrane of Raji cells would recognize the mPEG of PLD to cause the “second attack” of PLD by enhancing the internalization of PLD and enhance the therapeutic efficacy

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us